Insulet Announces Proposed Financing Transactions
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced plans to offer $450 million in senior unsecured notes due 2033 through a private placement. The company intends to use the proceeds, along with cash on hand, to manage its existing 0.375% Convertible Senior Notes due 2026.
Additionally, Insulet plans to amend its Credit Agreement to extend its revolving credit facility maturity from 2028 to 2030 and increase revolving credit commitments by up to $200 million, potentially reaching aggregate commitments of up to $500 million. Both transactions are subject to market conditions and may not proceed as described.
The Notes will be exclusively offered to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S of the Securities Act of 1933.
Insulet (NASDAQ: PODD), leader nella tecnologia delle pompe per insulina senza tubi, ha annunciato piani per offrire 450 milioni di dollari in note senior non garantite con scadenza nel 2033 tramite un collocamento privato. L'azienda intende utilizzare i proventi, insieme alla liquidità disponibile, per gestire le sue attuali Note Senior Convertibili allo 0.375% in scadenza nel 2026.
Inoltre, Insulet prevede di modificare il suo Accordo di Credito per estendere la scadenza della sua linea di credito revolving dal 2028 al 2030 e aumentare gli impegni di credito revolving fino a 200 milioni di dollari, raggiungendo potenzialmente impegni complessivi fino a 500 milioni di dollari. Entrambe le operazioni sono soggette alle condizioni di mercato e potrebbero non procedere come descritto.
Le Note saranno offerte esclusivamente a investitori istituzionali qualificati ai sensi della Regola 144A e a persone non statunitensi al di fuori degli Stati Uniti ai sensi della Regolamentazione S del Securities Act del 1933.
Insulet (NASDAQ: PODD), líder en tecnología de bombas de insulina sin tubo, ha anunciado planes para ofrecer 450 millones de dólares en notas senior no garantizadas con vencimiento en 2033 a través de una colocación privada. La empresa tiene la intención de utilizar los ingresos, junto con el efectivo disponible, para gestionar sus actuales Notas Senior Convertibles al 0.375% con vencimiento en 2026.
Además, Insulet planea enmendar su Acuerdo de Crédito para extender el vencimiento de su línea de crédito revolvente de 2028 a 2030 y aumentar los compromisos de crédito revolvente hasta 200 millones de dólares, alcanzando potencialmente compromisos agregados de hasta 500 millones de dólares. Ambas transacciones están sujetas a las condiciones del mercado y pueden no llevarse a cabo como se describe.
Las Notas se ofrecerán exclusivamente a compradores institucionales calificados bajo la Regla 144A y a personas no estadounidenses fuera de los Estados Unidos bajo la Regulación S de la Ley de Valores de 1933.
인슐렛 (NASDAQ: PODD), 튜브 없는 인슐린 펌프 기술의 선두주자로, 2033년 만기 4억 5천만 달러의 고급 무담보 채권을 사모로 발행할 계획을 발표했습니다. 이 회사는 수익금을 기존의 2026년 만기 0.375% 전환 사채를 관리하는 데 사용할 예정입니다.
또한, 인슐렛은 2028년에서 2030년으로 회전 신용 한도의 만기를 연장하고 회전 신용 약정을 최대 2억 달러까지 증가시키는 내용을 포함하여 신용 계약을 수정할 계획입니다. 이로 인해 총 약정이 최대 5억 달러에 이를 수 있습니다. 두 거래 모두 시장 조건에 따라 달라질 수 있으며, 설명된 대로 진행되지 않을 수도 있습니다.
채권은 144A 규정에 따라 자격을 갖춘 기관 투자자에게 독점적으로 제공되며, 1933년 증권법의 S 규정에 따라 미국 외의 비 미국인에게 제공됩니다.
Insulet (NASDAQ: PODD), leader dans la technologie des pompes à insuline sans tube, a annoncé des projets pour offrir 450 millions de dollars de billets senior non garantis arrivant à échéance en 2033 par le biais d'un placement privé. L'entreprise prévoit d'utiliser les produits, ainsi que les liquidités disponibles, pour gérer ses billets senior convertibles à 0,375% arrivant à échéance en 2026.
De plus, Insulet prévoit de modifier son Accord de Crédit pour étendre l'échéance de sa facilité de crédit renouvelable de 2028 à 2030 et d'augmenter les engagements de crédit renouvelable jusqu'à 200 millions de dollars, atteignant potentiellement des engagements globaux allant jusqu'à 500 millions de dollars. Les deux transactions sont soumises aux conditions du marché et pourraient ne pas se dérouler comme décrit.
Les billets seront offerts exclusivement à des acheteurs institutionnels qualifiés en vertu de la règle 144A et à des personnes non américaines en dehors des États-Unis en vertu de la réglementation S du Securities Act de 1933.
Insulet (NASDAQ: PODD), ein führendes Unternehmen in der Technologie der tubeless Insulinpumpen, hat Pläne angekündigt, 450 Millionen Dollar an ungesicherten Senior Notes mit Fälligkeit 2033 über eine Privatplatzierung anzubieten. Das Unternehmen beabsichtigt, die Erlöse zusammen mit vorhandenen liquiden Mitteln zur Verwaltung seiner bestehenden 0,375% wandelbaren Senior Notes mit Fälligkeit 2026 zu verwenden.
Darüber hinaus plant Insulet, seine Kreditvereinbarung zu ändern, um die Fälligkeit seiner revolvierenden Kreditlinie von 2028 auf 2030 zu verlängern und die revolvierenden Kreditverpflichtungen um bis zu 200 Millionen Dollar zu erhöhen, was potenziell zu Gesamtverpflichtungen von bis zu 500 Millionen Dollar führen könnte. Beide Transaktionen unterliegen den Marktbedingungen und könnten möglicherweise nicht wie beschrieben durchgeführt werden.
Die Notes werden ausschließlich qualifizierten institutionellen Käufern gemäß Regel 144A und nicht-US-Personen außerhalb der Vereinigten Staaten gemäß Regelung S des Securities Act von 1933 angeboten.
- Increased financial flexibility with $200 million expansion in revolving credit facility
- Extended credit facility maturity by 2 years to 2030
- Potential improvement in debt structure through refinancing of convertible notes
- Taking on $450 million in new debt through senior notes
- Increased debt obligations may impact financial leverage
Insights
Insulet's proposed financing transactions represent a strategic debt restructuring rather than expanding its overall debt burden. The company plans to issue
Simultaneously, Insulet is enhancing its liquidity position by extending its revolving credit facility maturity from 2028 to 2030 and increasing available commitments by up to
The transaction appears to be primarily focused on liability management rather than raising substantial new capital. By extending debt maturities and potentially reducing dilution risk, management is taking a conservative approach to capital structure optimization. While the interest rate on the new notes remains unspecified (a key detail for assessing the financial impact), the transaction aligns with typical corporate finance strategies for managing debt profiles and ensuring adequate liquidity.
These moves suggest Insulet remains focused on maintaining financial stability while optimizing its capital structure for long-term operations in the competitive medical device market.
The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company’s existing capped call transactions relating to the Company’s existing
The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company’s revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to
The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and only to non-
The Notes have not been registered under the Securities Act or any applicable state securities laws. As a result, the Notes may not be offered or sold within
This press release does not and will not constitute an offer to sell or a solicitation of an offer to buy any securities nor will there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful under the securities laws of such state. Any offer of the Notes will be made only by means of a private offering memorandum. This press release does not and will not constitute an offer to repurchase the Convertible Senior Notes, nor do the statements herein constitute a notice of redemption under the indenture governing the Convertible Senior Notes.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Forward-Looking Statements:
This press release contains forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future, including the offering of the Notes, the use of proceeds from the offering of the Notes and the Credit Agreement amendments. These forward-looking statements are based on Insulet’s current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Insulet’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in Insulet’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled “Risk Factors”, and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307100889/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation